A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern.

导出 OA

翻译打印收藏纠错

第一作者： Lixiao,Xing

第一单位： Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai 200032, China.

作者： Lixiao,Xing ^[1] ; Xinfeng,Xu ^[2] ; Wei,Xu ^[1] ; Zezhong,Liu ^[1] ; Xin,Shen ^[1] ; Jie,Zhou ^[1] ; Ling,Xu ^[1] ; Jing,Pu ^[1] ; Chan,Yang ^[2] ; Yuan,Huang ^[2] ; Lu,Lu ^[1] ; Shibo,Jiang ^[1] ; Shuwen,Liu ^[2]

作者单位： Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai 200032, China. ^[1] State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China. ^[2]

关键词 5-Helix SARS-CoV-2 fusion inhibitor heptad repeat 1 heptad repeat 2 six-helix bundle variant of concern

主题词人类(Humans);膜糖蛋白类(Membrane Glycoproteins);病毒包膜蛋白质类(Viral Envelope Proteins)

DOI 10.3390/v14030597

PMID 35337003

发布时间 2022-04-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交